MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- CIPLA
CIPLA Share Price 
(CIPL)
Here is the latest stock price and chart of Cipla. For more details, see the Cipla company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Mar 25, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)526.85 | Open (Rs) 526.00 | High (Rs) 528.40 | Low (Rs) 516.65 |
| % Change0.00 | Volume 1,363,430 | Value (Rs) 722,200,638 | 52-Week H/L 678.00 / 483.75 |
| Live NSE Quotes | Mar 25, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)526.85 | Open (Rs) 525.60 | High (Rs) 528.70 | Low (Rs) 516.20 |
| % Change0.01 | Volume 1,874,898 | Value (Rs) 981,213,600 | 52-Week H/L 678.45 / 483.75 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 16.02 | P/E Ratio (x) 32.89 | Market Cap (Rs m) 423,698.04 | P/BV (x) 2.98 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
CIPLA Share Price Today:
CIPLA last traded price was up 0.0% to Rs 526.9 on the BSE. On the NSE, CIPLA last traded price was up 0.0% to Rs 526.9. The total volume of shares traded was 3.2 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.5%. And the benchmark S&P BSE SENSEX was at 37,808.9 (down 0.9%).
Over the last 30 days, the CIPLA share price is down 4.0%. And over the last one year, CIPLA share price is down 2.6%.
|
| |
Today's Market
Sensex Ends 355 Points Lower; Telecom and Realty Stocks Witness Selling(Closing)
India share markets continued their downtrend and ended their trading session on a negative note. At the closing bell, the BSE Sensex stood lower by 355 points (down 0.9%).
Related Views On News
CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)
Nov 12, 2018 | Updated on Nov 12, 2018For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)
Nov 10, 2017Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.
Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)
Oct 30, 2017Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)
Mar 19, 2019The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.
5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)
Mar 15, 20195 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.
This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)
Mar 19, 2019If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.
Elections Don't Matter!(The Honest Truth)
Mar 13, 2019Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.
Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)
Mar 13, 2019The elements that fueled profit growth for these two companies led to a surge in their stock prices.
MoreTRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA 8-QTR ANALYSIS
COMPARE CIPLA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.